The Prognostic Role of Hyperglycemia and Glucose Variability in Covid-related Acute Respiratory Distress Syndrome

Overview

Journal Diabetes Res Clin Pract

Specialty Endocrinology

Date 2021 Apr 4

PMID 33812902

Citations 8

Authors

Chiara Lazzeri

Manuela Bonizzoli

Stafano Batacchi

Simona di Valvasone

Marco Chiostri

Adriano Peris

Affiliations

Soon will be listed here.

Abstract

Aims: Due to heterogeneity on the prognostic role of glucose values and glucose variability in Novel Coronavirus (COVID) disease, we aimed at assessing the prognostic role for Intensive Care Unit (ICU) death of admission hyperglycaemia, peak glycemia and glucose variability in critically ill COVID patients: METHODS: 83 patients consecutively admitted for COVID-related Acute Respiratory Distress Syndrome (ARDS) from from 1st March to 1st October 2020.

Results: Non survivors were older, with more comorbidities and a more severe disease. Corticosteroids were used in the majority of patients (54/83, 65%) with no difference between survivors and non survivors. Mean blood glucose values, (during the first 24 and 48 h, respectively), were comparable between the two subgroups, as well as SD 24 and CV 24. During the first 48 h, survivors showed significantly lower values of SD 48 (p < 0.001) and CV 48, respectively (p < 0.001) than non survivors.

Conclusions: in consecutive COVID-related ARDS patients admitted to ICU hyperglycemia (>180 mg/dl) is more common in non survivors who also showed a significantly higher glucose variability in the first 48 h since ICU admission. Our findings point to the clinical significance of in-ICU glucose control in severe COVID patients.

Citing Articles

Secondary Analysis of Fluids and Catheters Treatment Trial (FACTT) data reveal poor clinical outcomes in acute respiratory distress syndrome patients with diabetes.

Alanazi A, Almuntashiri S, Sikora A, Zhang D, Somanath P Respir Med. 2024; 223:107540.

PMID: 38290602 PMC: 10985622. DOI: 10.1016/j.rmed.2024.107540.

Glycemic Variability As a Prognostic Factor for Mortality in Patients With Critical Illness: A Systematic Review and Meta-Analysis.

Hryciw B, Ghossein J, Rochwerg B, Meggison H, Fernando S, Kyeremanteng K Crit Care Explor. 2024; 6(1):e1025.

PMID: 38222872 PMC: 10786590. DOI: 10.1097/CCE.0000000000001025.

Hyperglycemia and glucose variability are associated with worse survival in mechanically ventilated COVID-19 patients: the prospective Maastricht Intensive Care Covid Cohort.

van Herpt T, van Rosmalen F, Hulsewe H, van der Horst-Schrivers A, Driessen M, Jetten R Diabetol Metab Syndr. 2023; 15(1):253.

PMID: 38057908 PMC: 10698889. DOI: 10.1186/s13098-023-01228-1.

Glycemic variability and mortality in oncologic intensive care units.

Oliveira A, Castro M, Lima D Rev Bras Enferm. 2023; 76(4):e20220812.

PMID: 37820156 PMC: 10561948. DOI: 10.1590/0034-7167-2022-0812.

Relationship between acute glucose variability and cognitive decline in type 2 diabetes: A systematic review and meta-analysis.

Chi H, Song M, Zhang J, Zhou J, Liu D PLoS One. 2023; 18(9):e0289782.

PMID: 37656693 PMC: 10473499. DOI: 10.1371/journal.pone.0289782.

References

Egi M, Bellomo R, Reade M . Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy?. Crit Care. 2009; 13(2):302. PMC: 2689479. DOI: 10.1186/cc7755. View

Sachdeva S, Desai R, Gupta U, Prakash A, Jain A, Aggarwal A . Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature. SN Compr Clin Med. 2020; 2(11):2161-2166. PMC: 7550017. DOI: 10.1007/s42399-020-00575-8. View

Ceriello A . Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. Diabetes Res Clin Pract. 2020; 163:108186. PMC: 7188620. DOI: 10.1016/j.diabres.2020.108186. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Ilias I, Jahaj E, Kokkoris S, Zervakis D, Temperikidis P, Magira E . Clinical Study of Hyperglycemia and SARS-CoV-2 Infection in Intensive Care Unit Patients. In Vivo. 2020; 34(5):3029-3032. PMC: 7652529. DOI: 10.21873/invivo.12136. View

Bonizzoli M, Zagli G, Lazzeri C, DeglInnocenti S, Gensini G, Peris A . Early insulin resistance in severe trauma without head injury as outcome predictor? A prospective, monocentric pilot study. Scand J Trauma Resusc Emerg Med. 2012; 20:69. PMC: 3547687. DOI: 10.1186/1757-7241-20-69. View

Olariu E, Pooley N, Danel A, Miret M, Preiser J . A systematic scoping review on the consequences of stress-related hyperglycaemia. PLoS One. 2018; 13(4):e0194952. PMC: 5889160. DOI: 10.1371/journal.pone.0194952. View

Meyfroidt G . Blood glucose amplitude variability in critically ill patients. Minerva Anestesiol. 2014; 81(9):1010-8. View

Lemkes B, Hermanides J, DeVries J, Holleman F, Meijers J, Hoekstra J . Hyperglycemia: a prothrombotic factor?. J Thromb Haemost. 2010; 8(8):1663-9. DOI: 10.1111/j.1538-7836.2010.03910.x. View

10.

Egi M, Bellomo R . Reducing glycemic variability in intensive care unit patients: a new therapeutic target?. J Diabetes Sci Technol. 2010; 3(6):1302-8. PMC: 2787030. DOI: 10.1177/193229680900300610. View

11.

Ceriello A . Hyperglycemia and COVID-19: What was known and what is really new?. Diabetes Res Clin Pract. 2020; 167:108383. PMC: 7445137. DOI: 10.1016/j.diabres.2020.108383. View

12.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S . Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-943. PMC: 7070509. DOI: 10.1001/jamainternmed.2020.0994. View

13.

Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R . Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020; 14(4):813-821. PMC: 7673150. DOI: 10.1177/1932296820924469. View

14.

Le Gall J, Lemeshow S, Saulnier F . A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270(24):2957-63. DOI: 10.1001/jama.270.24.2957. View

15.

Ceriello A, Zarich S, Testa R . Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting. J Am Coll Cardiol. 2009; 53(5 Suppl):S9-13. DOI: 10.1016/j.jacc.2008.09.054. View

16.

Gunst J, De Bruyn A, Van den Berghe G . Glucose control in the ICU. Curr Opin Anaesthesiol. 2019; 32(2):156-162. PMC: 6774765. DOI: 10.1097/ACO.0000000000000706. View

17.

Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y . Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020; 63(10):2102-2111. PMC: 7347402. DOI: 10.1007/s00125-020-05209-1. View

18.

Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini G . In-hospital peak glycemia and prognosis in STEMI patients without earlier known diabetes. Eur J Cardiovasc Prev Rehabil. 2010; 17(4):419-23. DOI: 10.1097/HJR.0b013e328335f26f. View

19.

Lazzeri C, Valente S, Chiostri M, Attana P, Gensini G . Early glucose variability in cardiogenic shock following acute myocardial infarction: a pilot study. Ther Adv Cardiovasc Dis. 2015; 9(4):127-32. DOI: 10.1177/1753944715578968. View

20.

Yang Y, Cai Z, Zhang J . Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis. Biosci Rep. 2021; 41(2). PMC: 7876597. DOI: 10.1042/BSR20203584. View